1 – 19 of 19
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Structured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
(
- Contribution to journal › Letter
-
Mark
Change in health-related quality of life at early follow-up in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
(
- Contribution to journal › Article
- 2023
-
Mark
Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Societal costs associated to chronic thromboembolic pulmonary hypertension : A study utilizing linked national registries
(
- Contribution to journal › Article
-
Mark
Risk assessment in pulmonary arterial hypertension : A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
(
- Contribution to journal › Letter
-
Mark
Quality of life and functional status after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension : A Swedish single-center study
(
- Contribution to journal › Article
-
Mark
Societal costs associated with pulmonary arterial hypertension : A study utilizing linked national registries
(
- Contribution to journal › Article
-
Mark
Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?
(
- Contribution to journal › Letter
-
Mark
Aggrecan accumulates at sites of increased pulmonary arterial pressure in idiopathic pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2022
-
Mark
Prevalence of potential drug-drug interactions with disease-specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension : A registry study
(
- Contribution to journal › Article
-
Mark
Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2021
-
Mark
Vasodilator therapy for pulmonary hypertension in children : a national study of patient characteristics and current treatment strategies
(
- Contribution to journal › Article
-
Mark
Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2020
-
Mark
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy : a registry-based study
(
- Contribution to journal › Article
-
Mark
Outpatient specialist clinics for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification
(
- Contribution to journal › Article
- 2019
-
Mark
Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2016
-
Mark
Versican accumulates in vascular lesions in pulmonary arterial hypertension
(
- Contribution to journal › Article